Free Trial

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 42 -3.00 (-6.67%)
As of 10/17/2025 11:48 AM Eastern

SPEC vs. TSTL, BVC, AKR, CNSL, ODX, CTEC, AMS, ARIX, ANCR, and CIR

Should you be buying INSPECS Group stock or one of its competitors? The main competitors of INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Cambridge Nutritional Sciences (CNSL), Omega Diagnostics Group (ODX), ConvaTec Group (CTEC), Advanced Medical Solutions Group (AMS), Arix Bioscience (ARIX), Animalcare Group (ANCR), and Circassia Group (CIR). These companies are all part of the "medical" sector.

INSPECS Group vs. Its Competitors

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Tristel had 6 more articles in the media than INSPECS Group. MarketBeat recorded 6 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.98 beat INSPECS Group's score of 0.00 indicating that Tristel is being referred to more favorably in the media.

Company Overall Sentiment
Tristel Positive
INSPECS Group Neutral

Tristel has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, INSPECS Group has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£46.46M3.61£6.54M£0.132,720.93
INSPECS Group£195.28M0.22-£4.11M-£0.08-521.09

37.8% of Tristel shares are owned by institutional investors. Comparatively, 27.1% of INSPECS Group shares are owned by institutional investors. 21.1% of Tristel shares are owned by insiders. Comparatively, 20.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tristel has a net margin of 15.47% compared to INSPECS Group's net margin of -2.10%. Tristel's return on equity of 20.43% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.47% 20.43% 9.89%
INSPECS Group -2.10%-4.00%0.45%

Tristel currently has a consensus target price of GBX 400, indicating a potential upside of 13.96%. INSPECS Group has a consensus target price of GBX 60, indicating a potential upside of 42.86%. Given INSPECS Group's stronger consensus rating and higher probable upside, analysts clearly believe INSPECS Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Tristel beats INSPECS Group on 11 of the 16 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£42.70M£3.37B£6.20B£2.57B
Dividend Yield2.00%2.04%5.70%5.37%
P/E Ratio-521.09254.2485.704,124.89
Price / Sales0.2290.45580.7899,406.89
Price / Cash1.63146.5437.1027.90
Price / Book0.422.3612.238.11
Net Income-£4.11M£99.80M£3.33B£5.89B
7 Day Performance-7.69%0.89%1.17%-0.62%
1 Month Performance3.70%0.93%6.85%0.73%
1 Year Performance-25.66%114.75%58.93%128.71%

INSPECS Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
N/AGBX 42
-6.7%
GBX 60
+42.9%
-26.1%£42.70M£195.28M-521.091,673
TSTL
Tristel
1.2418 of 5 stars
GBX 355.13
-2.0%
GBX 400
+12.6%
-11.1%£169.48M£43.56M2,752.91208News Coverage
Earnings Report
High Trading Volume
BVC
BATM Advanced Communications
N/AGBX 19.60
+2.6%
N/A+5.5%£85.59M£118.82M-328.86980High Trading Volume
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32M-0.44120
CNSL
Cambridge Nutritional Sciences
N/AGBX 2.80
-3.4%
N/A-25.4%£6.66M£8.33M400.003,200Gap Down
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55M-220.0091Gap Down
CTEC
ConvaTec Group
4.0199 of 5 stars
GBX 242
+0.8%
GBX 309.40
+27.9%
+4.3%£4.86B£2.36B2,283.0210,000News Coverage
AMS
Advanced Medical Solutions Group
2.5217 of 5 stars
GBX 223.72
-1.4%
GBX 273.67
+22.3%
+6.4%£483.65M£220.30M5,365.0810Positive News
High Trading Volume
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
ANCR
Animalcare Group
N/AGBX 226
-1.7%
N/A-2.7%£155.92M£81.07M6,277.78220News Coverage
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down

Related Companies and Tools


This page (LON:SPEC) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners